Embolotherapy Market

Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser (Hospital, Clinics, ASC) - Global Forecast to 2026

Report Code: MD 7279 May, 2021, by marketsandmarkets.com

[230 Pages Report] The global embolotherapy market is valued at USD 3.4 billion in 2021 and is expected to reach USD 5.0 billion by 2026, at a CAGR of 8.0% during the forecast period. Increasing incidences of peripheral vascular diseases, liver cancer, strokes, and uterine fibroids coupled with rising preference for minimally invasive procedures; increasing investments, funds, and grants by public-private organizations for research; and technological advancements in the market will fuel the market growth over the forecast period.

Embolotherapy Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on the global embolotherapy market

The embolotherapy market is witnessing a loss of business, and the trend is expected to continue till December 2020. Unfavorable changes in regulations and guidelines are hampering the growth of this industry. Major regulatory authorities across the globe (such as CDC, WHO, MHRA, TGA, and EMA) have identified that cancer patients are at greater risk of COVID-19 infection than healthy adults. Thus, screening, diagnostic exams, and surgical procedures are being severely restricted or postponed at hospitals and cancer care centers. This is expected to cause disruption in the embolotherapy market.

Embolotherapy Market Dynamics

Driver: Growing target population

The embolotherapy devices market has experienced steady growth over the last decade, owing to the growing target patient population base, which has increased the number of target surgeries performed. CVD is a key target disease; its importance and high prevalence have made it a focus for research on successful and effective therapies. As of 2017, more than 200 million people are suffering from peripheral vascular diseases globally (Source: Elsevier, 2018). According to the same source, the prevalence of these diseases rises with age, with the above-80 age group displaying a prevalence rate of greater than 20%.

The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer will further boost the demand for embolotherapy devices in the near future. Liver cancer is fifth-most-common cancer in men and the ninth-most-common in women. Globally, there were over 840,000 new cases diagnosed in 2018. (Source: World Cancer Research Fund). Furthermore, over the last decade, kidney cancer incidence rates increased by 42% in the UK. In females, the incidence rates increased by 44%, while there was a 38% incidence rate in males. (Source: Cancer Research UK).

Restraint: Strong market positioning of alternative therapies

The availability of effective conventional first-level therapies for the treatment of liver cancer, uterine fibroids, hemorrhagic stroke, and other hemorrhagic conditions is a key restraint to market growth. For instance, therapies such as surgery, chemotherapy, and radiation therapy are preferred options in cancer treatment due to the high awareness among individuals about traditional cancer treatments, low adoption of advanced treatment options (especially in developing countries), and the reluctance among oncologists to shift from conventional treatment options.

Opportunity: Expanding applications of embolotherapy devices

The applications of embolotherapy continue to expand. Initially, embolotherapy was applied for uncontrolled gastrointestinal bleeding; in recent years, embolotherapy is being increasingly adopted for various indications such as non-operative management of solid tumors of the liver, spleen, and kidney; visceral and solid organ aneurysm; vascular malformations in the central nervous systems, pulmonary circulation, head & neck, trunk, and extremities; uterine fibroids; and benign prostatic tumors.

Challenge: Dearth of skilled surgeons

Healthcare markets are witnessing a dearth of well-trained surgeons (including neurosurgeons and radiologists). The Association of American Medical Colleges (US) has estimated a deficit of 41,000 general surgeons in the US by 2025 (Source: Association of American Medical Colleges US, 2017). A shortage of more than 2,300 medical oncologists is expected in the US by 2025 (Source: Journal of Global Oncology). Similarly, India is also facing an acute shortage of oncologists, radiotherapists, and surgical oncologists. With 1.8 million cancer patients in the country, there is only one oncologist to treat every 2,000 patients. The shortage of oncologists and radiologists in several countries worldwide is expected to affect the adoption of embolotherapy procedures.

Embolotherapy Market Ecosystem

To know about the assumptions considered for the study, download the pdf brochure

The microspheres segment accounted for the largest share of the embolotherapy market, by product, in 2020

Based on product, the embolotherapy market is broadly segmented into embolization coils (detachable coils and pushable coils), embolic agents (liquid embolic agents and microspheres), detachable balloons, embolic plug systems, and support devices (microcatheters and guidewires). The microspheres segment under embolic agents held the largest share of the market in 2020. The market growth of this segment is majorly driven by the surge in the prevalence of hepatocellular carcinoma (microspheres are widely used to treat this disease), coupled with favorable reimbursement criteria in developed economies. Moreover, new product launches and approvals are further supporting the growth of this segment.

The application segment, by cancer, to register significant growth over the forecast period

In terms of application, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The cancer segment commanded the largest share of the market in 2020, and the same segment will grow at the highest CAGR over the forecast period between 2021 and 2026. Rising incidences of liver cancer & kidney cancer coupled with respective adoption of TACE and TARE procedures will support the market growth.

Transcatheter Arterial Embolization (TAE) procedure attributes to rising preference for minimally invasive surgeries

On the basis of procedure, the embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial chemoembolization (TACE), and transcatheter arterial radioembolization (TARE)/selective internal radiation therapy (SIRT). The increasing demand for minimally invasive procedures, growing prevalence of chronic diseases, and rapid growth in the geriatric population are some of the key factors contributing to the large share of the transcatheter arterial embolization segment.

The Hospitals and Clinics end user segment garnered the highest revenue in the embolotherapy market in 2020

Based on end user, the embolotherapy market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users. Hospitals and clinics are the key end users of embolotherapy devices. This segment covers the market for embolotherapy devices used in big hospitals, small clinics, and critical care units. The growing adoption of minimally invasive surgical procedures (including vascular, urological, and neurological), increasing purchasing power of major healthcare providers across developed countries (owing to the consolidation of healthcare providers), and the greater availability of reimbursements for target procedures in the US and major European countries are the major factors that are expected to drive the demand for embolization devices in hospitals and clinics.

Embolotherapy Market by Region

The Asia Pacific market is expected to grow at the highest CAGR during the forecast period

The embolotherapy market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Improving healthcare infrastructure in the region, the large patient population for target diseases, and expanding presence of key market players in the region to grab elevating opportunities offered by these countries are the key factors supporting the market growth in this region.

Key Market Players

The major players in the embolotherapy market are Boston Medical Corporation (US), Terumo Medical Systems (Japan), Medtronic (US), Johnson & Johnson (US), and Stryker Corporation (US). Other key players in the embolization therapy market include Sirtex Medical Limited (US), Abbott Laboratories (US), Acandis GmbH (Germany), Balt (France), Cook Medical (US), Kaneka Corporation (Japan), Penumbra, Inc. (US), Merit Medical Systems (US), Meril Life Sciences Pvt. Ltd. (India), Cardiva (US), Shape Memory Medical Inc. (US), Artio Medical Inc. (US), Rapid Medical (US), Emboline, Inc. (US), and IMbiotechnologies Ltd. (Canada), among others.

Boston Scientific Corporation (US) holds a significant share in the embolotherapy market. The company majorly focuses on growth strategies such as acquisitions and expansions to increase its market presence and product offerings. In addition, the company’s acquisition of BTG has driven its sales and increased market share in the market. This is a major factor, which will help Boston Scientific to expand its product offerings in chemoembolization, radioembolization, and ablation therapies from BTG. Boston Scientific constantly strives to gain regulatory and reimbursement approvals. As a part of its long-term growth strategy, the company invests in fast-growing markets as well as new markets by strengthening its position in the global healthcare market.

Scope of the report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD billion)

Segments covered

Product, Application, Procedure, End User, and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

The major players in the market include Boston Scientific Corporation (US), Merit Medical Systems (US), Terumo Corporation (Japan), Medtronic plc (Ireland), Johnson & Johnson (US), Stryker Corporation (US), BTG plc (UK), Penumbra, Inc. (US), Cook Medical (US), Abbott Laboratories (US), Acandis GmbH (Germany), BALT Extrusion (France), Sirtex Medical Limited (Australia), Kaneka Corporation (Japan), and Meril Life Sciences Pvt. Ltd. (India) among others.

This report has segmented the global embolotherapy market based on product, application, procedure, end user, and region.

Global Embolotherapy market, by Product

  • Embolization Coil
    • Detachable Coils
    • Pushable Coils
  • Embolic Agents
    • Liquid Embolic Agents
    • Microspheres
  • Detachable Balloons
  • Embolic Plug Systems
  • Support Devices
    • Guidewires
    • Microcatheters

Global Embolotherapy market, by Application

  • Oncology
    • Liver Cancer
    • Kidney Cancer
    • Lung Cancer
    • Breast Cancer
    • Other Cancers
  • Peripheral Vascular Diseases
  • Urology and Nephrology
    • Benign Prostatic Hyperplasia
    • Uterine Fibroids
    • Other Urology and Nephrology Applications
  • Neurology
    • Brain Aneurysm
    • Cerebral Arteriovenous Malformations
  • GIT Disorders

Global Embolotherapy market, by Procedure

  • Transcatheter Arterial Embolization
  • Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
  • Transarterial Chemoembolization

Global Embolotherapy market, by End User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Global Embolotherapy market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • RoLA
  • Middle East & Africa

Recent Developments

  • In 2021, Boston Scientific has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere Y-90 Glass Microspheres.
  • In 2021, Terumo Corporation has the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide-neck bifurcation aneurysms
  • In 2020, Kaneka has Received FDA approval of the TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY USED FOR THE STUDY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
        FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 An indicative list of secondary sources
           2.1.2 PRIMARY DATA
                 FIGURE 2 BREAKDOWN OF PRIMARIES: EMBOLOTHERAPY MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
        FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 PRODUCT-BASED MARKET ESTIMATION
                 FIGURE 4 MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
        FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 44)
  FIGURE 6 EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
  FIGURE 7 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
  FIGURE 8 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)
  FIGURE 9 EMBOLOTHERAPY MARKET SHARE, BY END USER, 2021 VS. 2026
  FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE EMBOLOTHERAPY MARKET

4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 EMBOLOTHERAPY: MARKET OVERVIEW
        FIGURE 11 THE RISING INCIDENCE OF CHRONIC DISEASES IS A KEY FACTOR DRIVING MARKET GROWTH
    4.2 GEOGRAPHIC ANALYSIS: NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS 2026, (USD MILLION)
        FIGURE 12 THE EMBOLIC AGENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2026
    4.3 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS 2026, (USD MILLION)
        FIGURE 13 THE LIVER CANCER SUBSEGMENT OF THE ONCOLOGY APPLICATION IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    4.4 EMBOLOTHERAPY MARKET, BY REGION AND PROCEDURE
        FIGURE 14 TRANSARTERIAL EMBOLIZATION (TAE) PROCEDURE SEGMENT TO HOLD A MAJOR SHARE OF THE ASIA PACIFIC MARKET
    4.5 GEOGRAPHIC ANALYSIS: EMBOLOTHERAPY MARKET, BY END USER AND REGION, 2021 VS. 2026 (USD MILLION)
        FIGURE 15 AMBULATORY SURGICAL CENTERS SEGMENT TO WITNESS HIGH GROWTH IN EUROPE DURING THE FORECAST PERIOD
    4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOTHERAPY MARKET
        FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 17 EMBOLOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing target patient population
                            TABLE 1 PRIMARY INCIDENCE OF LIVER CANCER AMONG MEN AND WOMEN (2005 VS. 2030)
                            TABLE 2 GERIATRIC POPULATION, BY REGION (2015 VS. 2030)
                    5.2.1.2 Rising patient preference for minimally invasive procedures
                    5.2.1.3 Funding & investments by government and private organizations
                    5.2.1.4 Technological advancements in embolotherapy devices
                    5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries
                            TABLE 3 MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2021)
                            TABLE 4 MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019)
           5.2.2 RESTRAINTS
                    5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario
                    5.2.2.2 Strong market positioning of alternative therapies
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities offered by emerging markets
                    5.2.3.2 Expanding applications of embolization devices
           5.2.4 CHALLENGES
                    5.2.4.1 A dearth of skilled surgeons
                    5.2.4.2 High cost of embolization devices
    5.3 VALUE CHAIN ANALYSIS
        FIGURE 18 VALUE CHAIN ANALYSIS
    5.4 ECOSYSTEM: EMBOLOTHERAPY MARKET
    5.5 REGULATORY ANALYSIS
           5.5.1 NORTH AMERICA
                    5.5.1.1 US
                            TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
                            TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                    5.5.1.2 Canada
                            TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
                            FIGURE 19 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
           5.5.2 EUROPE
                 FIGURE 20 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR)
           5.5.3 ASIA PACIFIC
                    5.5.3.1 Japan
                            TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
                    5.5.3.2 China
                            TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.5.3.3 India
    5.6 IMPACT OF COVID-19 ON EMBOLOTHERAPY MARKET
        TABLE 10 COVID-19 GUIDELINES FOR TRIAGE OF VASCULAR SURGERY PATIENTS

6 EMBOLOTHERAPY MARKET, BY PRODUCT (Page No. - 72)
    6.1 INTRODUCTION
        TABLE 11 EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 EMBOLIC AGENTS
        TABLE 12 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 13 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY REGION, 2019–2026 (USD MILLION)
        TABLE 14 EMBOLIC AGENTS, BY TYPE
           6.2.1 LIQUID EMBOLIC AGENTS
                    6.2.1.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict the market growth
                            TABLE 15 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2019–2026 (USD MILLION)
                    6.2.1.2 Embolotherapy market for liquid embolic agents, by application
                            TABLE 16 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY APPLICATION, 2019–2026 (USD MILLION)
                    6.2.1.3 Embolotherapy market for liquid embolic agents, by Procedure
                            TABLE 17 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY PROCEDURE, 2019–2026 (USD MILLION)
                    6.2.1.4 Embolotherapy market for liquid embolic agents, by end user
                            TABLE 18 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY END USER, 2019–2026 (USD MILLION)
           6.2.2 MICROSPHERES
                    6.2.2.1 Preference for alternative procedures limits the growth of this market segment
                            TABLE 19 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY REGION, 2019–2026 (USD MILLION)
                    6.2.2.2 Embolotherapy market for microspheres, by application
                            TABLE 20 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY APPLICATION, 2019–2026 (USD MILLION)
                    6.2.2.3 Embolotherapy market for microspheres, by Procedure
                            TABLE 21 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY PROCEDURE, 2019–2026 (USD MILLION)
                    6.2.2.4 Embolotherapy market for microspheres, by end user
                            TABLE 22 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY END USER, 2019–2026 (USD MILLION)
    6.3 EMBOLIZATION COILS
        TABLE 23 EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS
        TABLE 24 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 25 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION, 2019–2026 (USD MILLION)
           6.3.1 DETACHABLE COILS
                    6.3.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment
                            TABLE 26 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION, 2019–2026 (USD MILLION)
                    6.3.1.2 Embolotherapy market for detachable coils, by application
                            TABLE 27 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY APPLICATION, 2019–2026 (USD MILLION)
                    6.3.1.3 Embolotherapy market for detachable coils, by Procedure
                            TABLE 28 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY PROCEDURE, 2019–2026 (USD MILLION)
                    6.3.1.4 Embolotherapy market for detachable coils, by end user
                            TABLE 29 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY END USER, 2019–2026 (USD MILLION)
           6.3.2 PUSHABLE COILS
                    6.3.2.1 The use of pushable coils increases the risk of non-target vascular blockages, thus restricting their use in various applications
                            TABLE 30 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION, 2019–2026 (USD MILLION)
                    6.3.2.2 Embolotherapy market for pushable coils, by application
                            TABLE 31 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY APPLICATION, 2019–2026 (USD MILLION)
                    6.3.2.3 Embolotherapy market for pushable coils, by Procedure
                            TABLE 32 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY PROCEDURE, 2019–2026 (USD MILLION)
                    6.3.2.4 Embolotherapy market for pushable coils, by end user
                            TABLE 33 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY END USER, 2019–2026 (USD MILLION)
    6.4 EMBOLIC PLUG SYSTEMS
        TABLE 34 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
           6.4.1 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION
                 TABLE 35 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION, 2019–2026 (USD MILLION)
           6.4.2 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE
                 TABLE 36 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE, 2019–2026 (USD MILLION)
           6.4.3 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER
                 TABLE 37 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER, 2019–2026 (USD MILLION)
    6.5 DETACHABLE BALLOONS
           6.5.1 ADVERSE EVENTS ASSOCIATED WITH THE USE OF DETACHABLE BALLOONS SUCH AS BALLOON RUPTURE, FAILURE, OR SHRINKAGE MAY LIMIT THE UTILIZATION OF THIS EMBOLIC DEVICE
                 TABLE 38 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION, 2019–2026 (USD MILLION)
           6.5.2 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION
                 TABLE 39 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION, 2019–2026 (USD MILLION)
           6.5.3 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE
                 TABLE 40 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE, 2019–2026 (USD MILLION)
           6.5.4 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER
                 TABLE 41 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER, 2019–2026 (USD MILLION)
    6.6 SUPPORT DEVICES
        TABLE 42 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
        TABLE 43 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION,  2019–2026 (USD MILLION)
           6.6.1 MICROCATHETERS
                    6.6.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption
                            TABLE 44 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION, 2019–2026 (USD MILLION)
                    6.6.1.2 Embolotherapy market for microcatheters, by application
                            TABLE 45 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY APPLICATION, 2019–2026 (USD MILLION)
                    6.6.1.3 Embolotherapy market for microcatheters, by Procedure
                            TABLE 46 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY PROCEDURE, 2019–2026 (USD MILLION)
                            TABLE 47 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY END USER, 2019–2026 (USD MILLION)
           6.6.2 GUIDEWIRES
                    6.6.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth
                            TABLE 48 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY REGION, 2019–2026 (USD MILLION)
                    6.6.2.2 Embolotherapy market for guidewires, by application
                            TABLE 49 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY APPLICATION, 2019–2026 (USD MILLION)
                    6.6.2.3 Embolotherapy market for guidewires, by Procedure
                            TABLE 50 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY PROCEDURE, 2019–2026 (USD MILLION)
                    6.6.2.4 Embolotherapy market for guidewires, by end user
                            TABLE 51 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY END USER, 2019–2026 (USD MILLION)

7 EMBOLOTHERAPY MARKET, BY APPLICATION (Page No. - 96)
    7.1 INTRODUCTION
        TABLE 52 EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026
    7.2 ONCOLOGY
        TABLE 53 EMBOLOTHERAPY MARKET FOR ONCOLOGY, BY TYPE, 2019–2026
        TABLE 54 EMBOLOTHERAPY MARKET FOR CANCER, BY REGION, 2019–2026
           7.2.1 LIVER CANCER
                    7.2.1.1 The rising prevalence of liver cancer is expected to drive segment growth
                            TABLE 55 EMBOLOTHERAPY MARKET FOR LIVER CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.2.2 KIDNEY CANCER
                    7.2.2.1 Preoperative kidney tumor embolization in the treatment of kidney cancer drives the segment growth
                            TABLE 56 EMBOLOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.2.3 LUNG CANCER
                    7.2.3.1 Use of arterial embolotherapy in patients with primary lung cancer to drive the segment growth
                            TABLE 57 EMBOLOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
                    7.2.3.2 The increasing prevalence of breast cancer is a key factor in the higher adoption of embolotherapy among surgeons
                            TABLE 58 EMBOLOTHERAPY MARKET FOR BREAST CANCER, BY REGION,  2019–2026 (USD MILLION)
           7.2.4 OTHER CANCERS
                 TABLE 59 EMBOLOTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
    7.3 PERIPHERAL VASCULAR DISEASES
           7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY FACTOR DRIVING MARKET GROWTH
                 TABLE 60 EMBOLOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)
    7.4 NEUROLOGY
        TABLE 61 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY TYPE, 2019–2026
        TABLE 62 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY REGION, 2019–2026 (USD MILLION)
           7.4.1 BRAIN ANEURYSM
                    7.4.1.1 Limited availability of reimbursements across major markets may hinder the market growth
                            TABLE 63 EMBOLOTHERAPY MARKET FOR BRAIN ANEURYSM, BY REGION, 2019–2026 (USD MILLION)
           7.4.2 CEREBRAL ARTERIOVENOUS MALFORMATION
                    7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent
                            TABLE 64 EMBOLOTHERAPY MARKET FOR CEREBRAL ARTERIOVENOUS MALFORMATION, BY REGION, 2019–2026 (USD MILLION)
    7.5 UROLOGY & NEPHROLOGY
        TABLE 65 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY TYPE,  2019–2026 (USD MILLION)
        TABLE 66 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY REGION, 2019–2026 (USD MILLION)
           7.5.1 BENIGN PROSTATIC HYPERPLASIA
                    7.5.1.1 Risks associated with traditional surgery will make patients opt for PAE treatment
                            TABLE 67 EMBOLOTHERAPY MARKET FOR BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2019–2026 (USD MILLION)
                    7.5.1.2 Advantages offered by the UFE over other techniques is a key factor driving market growth
                            TABLE 68 EMBOLOTHERAPY MARKET FOR UTERINE FIBROIDS, BY REGION, 2019–2026 (USD MILLION)
           7.5.2 OTHER UROLOGY & NEPHROLOGY APPLICATIONS
                    7.5.2.1 Safety and minimal complication with the use of TAE in this segment will drive the market growth
                            TABLE 69 EMBOLOTHERAPY MARKET FOR OTHER UROLOGY & NEPHROLOGY APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
    7.6 GASTROINTESTINAL DISORDERS
           7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB
                 TABLE 70 EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2019–2026 (USD MILLION)

8 EMBOLOTHERAPY MARKET, BY PROCEDURE (Page No. - 111)
    8.1 INTRODUCTION
        TABLE 71 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
    8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)
           8.2.1 THE GROWTH OF THIS SEGMENT IS LARGELY DRIVEN DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS
                 TABLE 72 TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
           8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE SUPPORTS THE GROWTH OF THIS SEGMENT
                 TABLE 73 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION, 2019–2026 (USD MILLION)
    8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE)
           8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION
                 TABLE 74 TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2019–2026

9 EMBOLOTHERAPY MARKET, BY END USER (Page No. - 117)
    9.1 INTRODUCTION
        TABLE 75 EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.2 HOSPITALS AND CLINICS
           9.2.1 RISING INCIDENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH
                 TABLE 76 EMBOLOTHERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019–2026 (USD MILLION)
    9.3 AMBULATORY SURGERY CENTERS
           9.3.1 INCREASING AVAILABILITY OF REIMBURSEMENTS TO DRIVE THE ADOPTION OF EMBOLOTHERAPY PRODUCTS IN ASCS
                 TABLE 77 EMBOLOTHERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2019–2026 (USD MILLION)
    9.4 OTHER END USERS
        TABLE 78 EMBOLOTHERAPY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

10 EMBOLOTHERAPY MARKET, BY REGION (Page No. - 121)
     10.1 INTRODUCTION
          TABLE 79 EMBOLOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
          FIGURE 21 NORTH AMERICA: EMBOLOTHERAPY MARKET SNAPSHOT
          TABLE 80 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 81 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
          TABLE 82 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 83 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 84 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 85 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
          TABLE 86 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
          TABLE 87 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Increasing R&D investments in the country drives the market growth
                                 TABLE 88 US: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 89 US: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 90 US: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 91 US: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 The rising prevalence of cancer supports market growth in Canada
                                 TABLE 92 CANADA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 93 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 94 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 95 CANADA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
     10.3 EUROPE
          TABLE 96 EUROPE: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 97 EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
          TABLE 98 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 99 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 100 EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 101 EUROPE: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
          TABLE 102 EUROPE: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
          TABLE 103 EUROPE: EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany is the fastest growing market in Europe
                                 TABLE 104 GERMANY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 105 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 106 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 107 GERMANY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 The rising geriatric population and the high incidence of chronic diseases support market growth in the UK
                                 TABLE 108 UK: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 109 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,  2019–2026 (USD MILLION)
                                 TABLE 110 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 111 UK: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 The growing geriatric population coupled with the increasing number of target surgeries to support market growth in France
                                 TABLE 112 FRANCE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 113 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 114 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 115 FRANCE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.3.4 SPAIN
                        10.3.4.1 Increasing government funding for research to support market growth
                                 TABLE 116 SPAIN: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 117 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 118 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 119 SPAIN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Rising awareness activities to support market growth
                                 TABLE 120 ITALY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 121 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,  2019–2026 (USD MILLION)
                                 TABLE 122 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 123 ITALY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
                    TABLE 124 REST OF EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 125 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 126 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 127 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
          FIGURE 22 ASIA PACIFIC: EMBOLOTHERAPY MARKET SNAPSHOT
          TABLE 128 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 129 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
          TABLE 130 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 131 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 132 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 133 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
          TABLE 134 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
          TABLE 135 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Presence of universal healthcare reimbursement scenario and growing geriatric population—key factors driving market growth
                                 TABLE 136 JAPAN: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 137 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 138 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 139 JAPAN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing patient pool and government initiatives for healthcare development supports market growth
                                 TABLE 140 CHINA: EMBOLOTHERAPY MARKET, BY PRODUCT,  2019–2026 (USD MILLION)
                                 TABLE 141 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 142 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 143 CHINA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Ongoing modernization and infrastructure development in India to support the market growth for embolotherapy
                                 TABLE 144 INDIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 145 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 146 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 147 INDIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Rising R&D and promising clinical trials in the country to positively impact market growth
                                 TABLE 148 SOUTH KOREA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 149 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 150 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 151 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 Rising research investments and awareness campaigns are the key factors supporting market growth in Australia
                                 TABLE 152 AUSTRALIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 153 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 154 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 155 AUSTRALIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
                    TABLE 156 REST OF APAC: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 157 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 158 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 159 REST OF APAC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
          TABLE 160 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
          TABLE 161 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
          TABLE 162 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 163 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 164 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 165 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
          TABLE 166 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
          TABLE 167 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Brazil is a key market in Latin America owing to the modernization of healthcare facilities
                                 TABLE 168 BRAZIL: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 169 BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 170 BRAZIL : EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 171 BRAZIL: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Availability of advanced care and increasing awareness programs are driving market growth in Mexico
                                 TABLE 172 MEXICO: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                 TABLE 173 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 174 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                                 TABLE 175 MEXICO: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                    TABLE 176 REST OF LATAM: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 177 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 178 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 179 REST OF LATAM: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN THE MEA
                    TABLE 180 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 181 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 182 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 183 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 184 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                    TABLE 185 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                    TABLE 186 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY END USER,  2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 174)
     11.1 OVERVIEW
          FIGURE 23 KEY DEVELOPMENTS IN THE EMBOLOTHERAPY MARKET FROM 2017 TO 2020
     11.2 GLOBAL MARKET SHARE ANALYSIS
             11.2.1 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS (2019)
                    FIGURE 24 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
     11.3 COMPETITIVE LEADERSHIP MAPPING
             11.3.1 STARS
             11.3.2 EMERGING LEADERS
             11.3.3 PERVASIVE
             11.3.4 PARTICIPANTS
                    FIGURE 25 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
                    FIGURE 26 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS)
     11.4 COMPETITIVE SCENARIO
             11.4.1 PRODUCT LAUNCHES
                    TABLE 187 EMBOLOTHERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, 2017–2020
             11.4.2 EXPANSIONS
                    TABLE 188 EMBOLOTHERAPY MARKET: EXPANSIONS, 2017–2020
             11.4.3 ACQUISITIONS
                    TABLE 189 EMBOLOTHERAPY MARKET: ACQUISITIONS, 2017–2020

12 COMPANY PROFILES (Page No. - 181)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
     12.1 KEY PLAYERS
             12.1.1 BOSTON SCIENTIFIC CORPORATION
                    TABLE 190 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
                    FIGURE 27 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
             12.1.2 MERIT MEDICAL SYSTEMS
                    TABLE 191 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW
                    FIGURE 28 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT
             12.1.3 TERUMO CORPORATION
                    TABLE 192 TERUMO CORPORATION: BUSINESS OVERVIEW
                    FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT
             12.1.4 MEDTRONIC PLC
                    TABLE 193 MEDTRONIC PLC: BUSINESS OVERVIEW
                    FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT
             12.1.5 ABBOTT LABORATORIES
                    TABLE 194 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                    FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT
             12.1.6 DEPUY SYNTHES (J&J MEDICAL DEVICES)
                    TABLE 195 DEPUY SYNTHES: BUSINESS OVERVIEW
                    FIGURE 32 JOHNSON & JOHNSON: COMPANY SNAPSHOT
             12.1.7 COOK MEDICAL
                    TABLE 196 COOK MEDICAL: BUSINESS OVERVIEW
             12.1.8 BALT
                    TABLE 197 BALT: BUSINESS OVERVIEW
             12.1.9 SIRTEX MEDICAL LIMITED (PART OF CDH INVESTMENTS)
                    TABLE 198 SIRTEX MEDICAL LIMITED: BUSINESS OVERVIEW
             12.1.10 KANEKA CORPORATION
                     TABLE 199 KANEKA CORPORATION: BUSINESS OVERVIEW
                     FIGURE 33 KANEKA CORPORATION: COMPANY SNAPSHOT
             12.1.11 STRYKER CORPORATION
                     TABLE 200 STRYKER CORPORATION: BUSINESS OVERVIEW
                     FIGURE 34 STRYKER CORPORATION: COMPANY SNAPSHOT
     12.2 OTHER PLAYERS
             12.2.1 PENUMBRA, INC.
                    TABLE 201 PENUMBRA, INC.: BUSINESS OVERVIEW
                    FIGURE 35 PENUMBRA, INC.: COMPANY SNAPSHOT
             12.2.2 MERIL LIFE SCIENCES PVT., LTD.
                    TABLE 202 MERIL LIFE SCIENCES PVT., LTD.: BUSINESS OVERVIEW
             12.2.3 ACANDIS GMBH
                    TABLE 203 ACANDIS GMBH: BUSINESS OVERVIEW
             12.2.4 CARDIVA MEDICAL INC. (PART OF HAEMONETICS)
                    TABLE 204 CARDIVA MEDICAL INC.: BUSINESS OVERVIEW
             12.2.5 SHAPE MEMORY MEDICAL, INC.
                    TABLE 205 SHAPE MEMORY MEDICAL, INC..: BUSINESS OVERVIEW
             12.2.6 ARTIO MEDICAL, INC.
                    TABLE 206 ARTIO MEDICAL, INC.: BUSINESS OVERVIEW
             12.2.7 RAPID MEDICAL
                    TABLE 207 RAPID MEDICAL: BUSINESS OVERVIEW
             12.2.8 IMBIOTECHNOLOGIES LTD.
                    TABLE 208 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW
             12.2.9 EMBOLINE, INC.
                    TABLE 209 EMBOLINE, INC.: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 222)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the embolotherapy market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Primary research was conducted after acquiring extensive knowledge about the global embolotherapy market scenario through secondary research. Primary interviews were conducted with market experts from both the demand-side (such as CROs, hospitals, transplant centers, healthcare service providers, commercial service providers, academia, and research organizations) and supply-side respondents (such as presidents, CEOs, vice presidents, directors, general managers, heads of business units, and senior managers) across five major geographies, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa. Approximately 60% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 40%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Embolotherapy Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

A detailed market estimation approach was followed to estimate and validate the size of the global embolotherapy market and other dependent submarkets.

  • The key players in the global embolotherapy market were identified through secondary research, and their global market shares were determined through primary and secondary research.
  • The research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights on the global embolotherapy market.
  • All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources.
  •  All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Embolotherapy Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation:

After deriving the overall Embolotherapy market value data from the market size estimation process, the total market value data was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all the segments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various qualitative and quantitative variables as well as by analyzing regional trends for both the demand- and supply-side macro indicators.

Report Objectives:

  • To define, describe, and forecast the embolotherapy market on the basis of product, disease indication, procedure, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the embolotherapy market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, Australia, South Korea, and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; business expansions and research & development activities in the embolotherapy market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global embolotherapy market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • Further breakdown of the Rest of Europe embolotherapy market into Belgium, Austria, the Czech Republic, Denmark, Greece, Poland, and Russia, among other
  • Further breakdown of the Rest of Asia Pacific embolotherapy market into wan, New Zealand, Vietnam, the Philippines, Singapore, Malaysia, Thailand, and Indonesia among other
  • Further breakdown of the Latin American embolotherapy market into Argentina, Chile, Peru, and Colombia, among other
COVID-19

Get in-depth analysis of the COVID-19 impact on the Embolotherapy Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Embolotherapy Market

Request For Special Pricing
Report Code
MD 7279
Published ON
May, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Embolotherapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home